Health Care & Life Sciences » Biotechnology | Progenics Pharmaceuticals Inc.

Progenics Pharmaceuticals Inc.

Progenics Pharmaceuticals Inc.
Stock Exchange Frankfurt Stock Exchange
EPS
 -
Market Cap
 -
Shares Outstanding
 84.45 M
Public Float
 52.34 M
Progenics Pharmaceuticals Inc.
Stock Exchange NASDAQ Stock Market
EPS
 $0.9
Market Cap
 $496.59 M
Shares Outstanding
 84.74 M
Public Float
 83.85 M

Profile

Address
One World Trade Center
New York New York 1000
United States
Employees -
Website http://www.progenics.com
Updated 07/08/2019
Progenics Pharmaceuticals, Inc. engages in the development of medicines and other products for targeting and treating cancer. Its pipeline includes therapeutic agents, imaging agents for prostate cancer, and imaging analysis technology. The company was founded by Paul J.

Financials

View All
Created with Highcharts 5.0.14Progenics Pharmaceuticals Inc.Net Income. Fiscal year is January-December. All values USD Thousands.42 57242 5724 4104 41039 11239 11210 80610 80651 01351 01367 65767 657201320142015201620172018020k40k60k80k
Created with Highcharts 5.0.14Progenics Pharmaceuticals Inc.Sales/Revenue. Fiscal year is January-December. All values USD Thousands.7 8627 86244 37744 3778 6768 67669 42969 42911 69811 69815 62215 622201320142015201620172018020k40k60k80k

Mark Robert Baker
Chief Executive Officer & Director
Peter J. Crowley
Chairman
View All

StatInvestor

Privacy Policy
Feedback

© 2025 StatInvestor All Rights Reserved.